Definitive Healthcare Seeks Shareholder Approval for 15 Million Share Equity Plan Increase
summarizeSummary
Definitive Healthcare Corp. filed a definitive proxy statement seeking shareholder approval to increase its equity incentive plan by 15 million shares, representing a potential 10.44% dilution.
check_boxKey Events
-
Proposed Equity Plan Expansion
Shareholders will vote on increasing the Definitive Healthcare Corp. 2021 Equity Incentive Plan by 15,000,000 shares, raising the total authorized from 30,972,789 to 45,972,789.
-
Significant Potential Dilution
The proposed increase represents a potential dilution of approximately 10.44% of the company's total outstanding shares, if all new shares were issued.
-
Annual Meeting Details
The Annual Meeting of Stockholders is scheduled for Thursday, June 4, 2026, where shareholders will vote on this and other proposals, including director elections and executive compensation.
-
Context of Financial Performance
This move to expand equity incentives comes after the company reported a 4% revenue decline and a $199.3 million net loss for fiscal year 2025, with a negative revenue growth outlook for 2026.
auto_awesomeAnalysis
Definitive Healthcare Corp. is seeking shareholder approval to significantly expand its 2021 Equity Incentive Plan by 15,000,000 shares, increasing the total authorized shares from 30,972,789 to 45,972,789. This proposal, if approved, represents a potential dilution of approximately 10.44% based on current outstanding shares. Given the company's recent financial performance, including a 4% revenue decline and a $199.3 million net loss in fiscal year 2025, this substantial increase in equity compensation highlights the company's reliance on stock-based incentives to attract and retain talent amidst challenging operational conditions. While necessary for employee motivation, the potential dilution could weigh on existing shareholder value.
At the time of this filing, DH was trading at $1.03 on NASDAQ in the Technology sector, with a market capitalization of approximately $142.8M. The 52-week trading range was $0.92 to $4.70. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.